Stock analysts at StockNews.com assumed coverage on shares of Axsome Therapeutics (NASDAQ:AXSM – Get Rating) in a research report issued on Thursday. The brokerage set a “sell” rating on the stock.
AXSM has been the topic of a number of other reports. Morgan Stanley dropped their price objective on shares of Axsome Therapeutics from $86.00 to $85.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 28th. BTIG Research upped their target price on shares of Axsome Therapeutics from $62.00 to $98.00 and gave the company a “buy” rating in a report on Friday, December 23rd. Bank of America restated an “underperform” rating and issued a $52.00 target price on shares of Axsome Therapeutics in a report on Tuesday, February 14th. HC Wainwright restated a “buy” rating and issued a $210.00 target price on shares of Axsome Therapeutics in a report on Monday, March 6th. Finally, SVB Leerink upped their target price on shares of Axsome Therapeutics from $65.00 to $85.00 and gave the company an “outperform” rating in a report on Tuesday, November 29th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $104.64.
Axsome Therapeutics Trading Down 0.8 %
Shares of NASDAQ:AXSM opened at $62.74 on Thursday. Axsome Therapeutics has a 52 week low of $20.63 and a 52 week high of $82.00. The company’s 50 day moving average is $66.01 and its two-hundred day moving average is $61.97. The company has a current ratio of 2.54, a quick ratio of 2.50 and a debt-to-equity ratio of 0.86. The company has a market cap of $2.73 billion, a PE ratio of -13.73 and a beta of 1.95.
Institutional Investors Weigh In On Axsome Therapeutics
Several hedge funds have recently modified their holdings of AXSM. JPMorgan Chase & Co. boosted its stake in shares of Axsome Therapeutics by 0.5% during the 1st quarter. JPMorgan Chase & Co. now owns 176,086 shares of the company’s stock worth $7,288,000 after purchasing an additional 843 shares during the last quarter. Raymond James Financial Services Advisors Inc. acquired a new stake in shares of Axsome Therapeutics during the 1st quarter worth about $732,000. MetLife Investment Management LLC boosted its stake in shares of Axsome Therapeutics by 59.0% during the 1st quarter. MetLife Investment Management LLC now owns 17,348 shares of the company’s stock worth $718,000 after purchasing an additional 6,439 shares during the last quarter. Panagora Asset Management Inc. acquired a new stake in shares of Axsome Therapeutics during the 1st quarter worth about $526,000. Finally, Sei Investments Co. boosted its stake in shares of Axsome Therapeutics by 1.3% during the 1st quarter. Sei Investments Co. now owns 146,363 shares of the company’s stock worth $6,059,000 after purchasing an additional 1,909 shares during the last quarter. 59.71% of the stock is owned by institutional investors and hedge funds.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14.
- Get a free copy of the StockNews.com research report on Axsome Therapeutics (AXSM)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.